TY - JOUR T1 - Line Probe Assay as a preliminary investigation for diagnosing resistant tuberculosis : A Single center experience JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.1592 VL - 56 IS - suppl 64 SP - 1592 AU - Deepak Muthreja AU - Rajesh Swarnakar AU - Anil Sontakke Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/1592.abstract N2 - Line probe assay and Cartridge Based Nucleic Acid Amplification Test are molecular method for rapid diagnosis of Tuberculosis. First line Line probe assay also called Genotype MTBDR plus detects Rifampicin and Isoniazid resistance. LPA detects rifampicin resistance by detecting rpoB mutation and isoniazid resistance by detecting both katG and inhA mutation. First line LPA has shown a sensitivity and specificity for the detection of Rif resistance of 96.7% and 98.8%, respectively, and for the detection of H resistance, a sensitivity and specificity of 90.2% and 99.2%, respectively for pulmonary tuberculosis.Usually GeneXpert is being done as a preliminary investigation for diagnosing resistant tuberculosis but it doesn’t detect isoniazid monoresistance. At our centre we evaluated utility of Line Probe Assay as preliminary test for both pulmonary and extrapulmonary for diagnosing resistant tuberculosis. Total of 239 samples were subjected for line probe assay, 172 being pulmonary and 67 being extrapulmonary. Tuberculosis was confirmed by cultures and histopathology in 170 patients, 127 being pulmonary and 43 extrapulmonary. LPA was positive in 151 patients in which isoniazid monoresistance was found in 26 patients (17 with katG and 9 with inhA), rifampicin monoresistance in 10 patients and 19 patients had both isoniazid and rifampicin resistance.Line probe assay has shown good accuracy in diagnosis of not only multidrug resistance but also INH & RIF monoresistance which carries significant treatment outcomes. The purpose of determining these resistances is to administer resistance appropriate proper regimen to the patient according to the results.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1592.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -